[EN] NK RECEPTOR ANTAGONISTS FOR CANCER PATIENTS<br/>[FR] ANTAGONISTES DU RÉCEPTEUR NK POUR PATIENTS ATTEINTS D'UN CANCER
申请人:[en]ACER THERAPEUTICS INC.
公开号:WO2022026900A2
公开(公告)日:2022-02-03
The present disclosure relates generally to a method of blocking, attenuating, or limiting the development of one or more vasomotor symptoms (VMS) in a patient who has cancer, has had cancer, or has an increased risk for cancer by administering a NK antagonist.